Grandfield & Dodd’s Alnylam Pharmaceuticals ALNY Stock Holding History

Grandfield & Dodd’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$834K	Buy	3,379 +175	+5%	+$44.5K	0.04%	125
2026 Q2	$964K	Buy	3,204 +123	+4%	+$37.1K	0.05%	115
2026 Q1	$1.02M	Sell	3,081 -48	-2%	-$16.3K	0.06%	108
2025 Q4	$1.24M	Buy	3,129 +9	+0.3%	+$3.98K	0.07%	105
2025 Q3	$1.42M	Buy	3,120 +68	+2%	+$27.7K	0.08%	100
2025 Q2	$995K	Buy	3,052 +20	+0.7%	+$5.53K	0.06%	109
2025 Q1	$819K	Buy	3,032 +659	+28%	+$169K	0.05%	111
2024 Q4	$558K	Buy	2,373 +1,149	+94%	+$302K	0.03%	135
2024 Q3	$337K	Buy	+1,224	New	+$319K	0.02%	164

Other funds holding ALNY

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Grandfield & Dodd's ALNY Position: Q3 2026 in Review

Grandfield & Dodd increased its Alnylam Pharmaceuticals (ALNY) stake by 5.5% in Q3 2026, buying an estimated $44.5K and bringing the position to 3,379 shares worth $834K. The position accounts for 0.04% of the portfolio, ranked #125.

Grandfield & Dodd first reported a position in ALNY in Q3 2024 and has held it in 9 quarters since. The position peaked at $1.42M in Q3 2025. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

Grandfield & Dodd held 3,379 shares of Alnylam Pharmaceuticals worth $834K as of Q3 2026.
Grandfield & Dodd bought 175 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $44.5K.
Alnylam Pharmaceuticals made up 0.04% of Grandfield & Dodd's portfolio in Q3 2026, its #125 holding.
Grandfield & Dodd first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
Grandfield & Dodd's Alnylam Pharmaceuticals position peaked at $1.42M in Q3 2025.
591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Grandfield & Dodd's 13F filing for Q3 2026, filed 29 Oct 2026.